Nordic Bioscience’s Post

Oncologists recently gathered at #ASCO2024 to discuss the latest in cancer research, with a major focus on biomarkers and antibody-drug conjugates (ADCs). Highlights included groundbreaking trial data for small molecules like Lorbrena and Tagrisso, emphasizing the effectiveness of targeted biomarker therapies. Notable advancements in biomarker technologies and individualized neoantigen therapies were also showcased, alongside challenges in ADC efficacy and safety. Future discussions will explore new biomarker detection methods and multitarget ADCs to enhance specificity and reduce side effects. To read the full CRA Insights by Aaron E., click here: https://crai.news/a88 #CRALifeSciences

New!📌 Validation of a multiomic model of #plasmaextracellularvesicle PD-L1 and radiomics for prediction of response to #immunotherapy in NSCLC ----------------------------- Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable predictive biomarkers. Here Christian Rolfo, MD, PhD, MBA,Dr.h.c. et al. showed preliminary data on the predictive role of the combination of radiomics and plasma extracellular vesicle (EV) PD-L1 to predict durable response to ICIs. Look here⤵️ https://lnkd.in/dbEeYh6y #LungCancer #Immunecheckpointinhibitor #LiquidBiopsy IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw

New!🦞 Circulating interleukin-8 and #osteopontin are promising biomarkers of clinical outcomes in advanced #melanoma patients treated with targeted therapy ------------------- Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. In this study by Stefania D'Atri et al plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseline (T0), after 2 months of therapy (T2) and, when feasible, at progression (TP), in 70 melanoma patients treated with BRAF and MEK inhibitors. The association of baseline cytokine levels with clinical response, progression-free survival (PFS) and overall survival (OS) was evaluated. Look here👇 https://lnkd.in/dE3cn4qW #CirculatingCytokines #Survival IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Last Sunday marked National Cancer Survivors Day Foundation, Inc., so we're honoring it with some hopeful news… Stanford University School of Medicine has become the first US center to treat a patient with advanced melanoma using Lifileucel, the first FDA-approved cell-based therapy for solid tumors. Lifileucel demonstrated promising results in clinical trials, with 30% of the 153 patients who received the therapy experiencing tumor shrinkage or disappearance. Among them, 40% showed no cancer progression for at least 18 months following the one-time infusion. As the momentum of therapy approvals continues to accelerate, it is imperative that we tackle today's manufacturing challenges now, to ensure that therapies are not only approvable but accessible and affordable too. Read more ➡️ https://lnkd.in/e9XDBbMj #ManufacturingBrighterFutures #AccelerateProductDevelopment  #AccelerateBetterBiology #PatientAccess #Biotechnology

Biomarker-informed treatment planning has expanded possibilities for people with #ColorectalCancer, especially those with metastatic disease. Biomarker test results can provide insight into a patient’s cancer type, predicted tumor response to specific treatment, dosing decisions, and more. ➡️ Discover how biomarker testing works: https://lnkd.in/g8F5uuYw

Exciting News for our community! A Phase 2 study has just started evaluating ulixertinib, a first-in-class ERK 1/2 inhibitor being developed by Biomed Valley Discoveries, for treating histiocytosis. This rare disorder causes abnormal white blood cell growth, leading to serious health issues. Dr. Eli Diamond from Memorial Sloan Kettering Cancer Center leads this study, building on promising results from patients who previously tried ulixertinib. This new approach could offer a breakthrough for those who don't respond to current treatments. We are hopeful that ulixertinib will bring a much-needed new treatment option for histiocytosis patients! Learn more about this exciting development by clicking this link: https://lnkd.in/enPPCnBT #Histiocytosis #Ulixertinib #BiomedValleyDiscoveries #NewHope #CancerResearch #ClinicalTrials #PatientCare #MedicalBreakthrough

Tertiary lymphoid structures (TLS) are lymph node-like organizations of immune cells within inflamed tissues that can drive immune cell activation. TLS has been a hot topic in the field of immuno-oncology, where it is believed they play a critical role in influencing the tumor microenvironment. Since TLSs are associated with improvement in clinical outcomes, their presence or induction following cancer therapies could be a valuable predictor of therapeutic responses. Stop by our blog to find out how our team studies tertiary lymphoid structures – a promising biomarker for immunotherapy. https://bit.ly/3FmiS6O #TertiaryLymphoidStructures #Biomarker #Immunotherapy #SpatialBiology

Check out our press release on the new study published in Nature Medicine!   This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC). In this study, PredicineBEACON™ showcased remarkable biomarker results and played an important role in evaluating treatment efficacy and identifying drug resistance mechanisms at the MRD level. Read more in our press release: https://lnkd.in/gS3apsH9 Read the full paper: https://lnkd.in/g7sKXHzf #liquidbiopsy #MRD #NGS  #NSCLC #CRC #lungcancer #precisionmedicine #oncology #clinicaltrial #CDx

“YB-1 is an important regulator of the translation of genetic messages into the synthesis of proteins. It appears to play a role in cancer progression and drug resistance in at least 21 types of cancer. In a recent paper in the journal Cell Reports Medicine, Malhotra and co-authors detail how SU056 acts against triple-negative breast cancer, an aggressive subtype that accounts for about one-fifth of breast cancer cases. In multiple cell lines modeling triple-negative breast cancer, SU056 inhibited growth and cell cycle progression, meaning cancer cells couldn't replicate as easily. In patient-derived xenograft models of triple-negative breast cancer—using samples that came from donors—doses of the drug given orally over 21 days inhibited tumor growth by up to 63%. In a model of tumor spreading, the SU056-treated group of animals had a 65.5% decrease in lung metastasis compared with the control group.” #cancerresearch #metastasis #cancertreatment #cancerprogression #cancer #tumormicroenvironment